Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy

31 July 2021 : Clinical Research

Xingqin Zhou^1BCE, Yazhou Chang^2BD, Jing Qian^1BF, Chaoyan Shen^1DEF, Jie Han^1EF, Hongyu Zhao^1DF, Renan Chang^3AG*

DOI: 10.12659/MSM.929474

Med Sci Monit 2021; 27:e929474

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Dose adjustment strategy of fluorouracil based on the AUC.

Gamelin, 2008 [11]		Wasif, 2009 [12]		Kaldate, 2012 [13]		Wilhelm, 201614		Denda, 201615
AUC	Adjustment range (%)	AUC	Adjustment range (%)	AUC	Adjustment range (%)	AUC	Adjustment range (%)	AUC	Adjustment range (%)
<4	70	<5	150	<8	30	<8	Repeat the original dose; if the AUC is <8 again, increase dose by 30%	<8	30
4–8	50	5–10	100	8–13	24	8–13	25	8–13	25
8–10	40	10–15	25	14–16	18	14–16	20	14–16	20
10–12	30	15–20	15	17–19	12	17–19	10	17–19	10
12–15	20	20–25	0	20–30	0	20–29	0	20–30	0
15–18	10	25–30	−10	30–33	−12	30–33	−10	30–33	−10
18–20	5	30–35	−15	34–36	−18	34–36	−20	34–36	−20
20–24	0	35–40	−20	37–39	−24	37–39	−25	37–39	−25
24–48	−5	–	–	≥40	−30	≥40	−30	≥40	−30
28–31	−10	–	–	–	–	–	–	–	–
>31	−15	–	–	–	–	–	–	–	–

Back to the Article